MA31706B1 - Formulations galéniques de composés organiques - Google Patents
Formulations galéniques de composés organiquesInfo
- Publication number
- MA31706B1 MA31706B1 MA32701A MA32701A MA31706B1 MA 31706 B1 MA31706 B1 MA 31706B1 MA 32701 A MA32701 A MA 32701A MA 32701 A MA32701 A MA 32701A MA 31706 B1 MA31706 B1 MA 31706B1
- Authority
- MA
- Morocco
- Prior art keywords
- minutes
- equal
- organic compounds
- dosage formulations
- pharmaceutically acceptable
- Prior art date
Links
- 238000009472 formulation Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 150000002894 organic compounds Chemical class 0.000 title 1
- 238000004090 dissolution Methods 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- UXOWGYHJODZGMF-QORCZRPOSA-N Aliskiren Chemical compound COCCCOC1=CC(C[C@@H](C[C@H](N)[C@@H](O)C[C@@H](C(C)C)C(=O)NCC(C)(C)C(N)=O)C(C)C)=CC=C1OC UXOWGYHJODZGMF-QORCZRPOSA-N 0.000 abstract 1
- 239000004072 C09CA03 - Valsartan Substances 0.000 abstract 1
- 229960004601 aliskiren Drugs 0.000 abstract 1
- 230000001747 exhibiting effect Effects 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- SJSNUMAYCRRIOM-QFIPXVFZSA-N valsartan Chemical compound C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SJSNUMAYCRRIOM-QFIPXVFZSA-N 0.000 abstract 1
- 229960004699 valsartan Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US97590107P | 2007-09-28 | 2007-09-28 | |
| US97592507P | 2007-09-28 | 2007-09-28 | |
| US97590907P | 2007-09-28 | 2007-09-28 | |
| US97591907P | 2007-09-28 | 2007-09-28 | |
| PCT/US2008/077416 WO2009045795A2 (en) | 2007-09-28 | 2008-09-24 | Galenical formulations of aliskiren and valsartan |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA31706B1 true MA31706B1 (fr) | 2010-09-01 |
Family
ID=40377183
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA32701A MA31706B1 (fr) | 2007-09-28 | 2010-03-17 | Formulations galéniques de composés organiques |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20100209480A1 (enExample) |
| EP (1) | EP2205233A2 (enExample) |
| JP (1) | JP2010540547A (enExample) |
| KR (1) | KR20100063090A (enExample) |
| CN (1) | CN101808631A (enExample) |
| AR (1) | AR066168A1 (enExample) |
| AU (1) | AU2008309058B2 (enExample) |
| BR (1) | BRPI0817442A2 (enExample) |
| CA (1) | CA2698330A1 (enExample) |
| CL (1) | CL2008002829A1 (enExample) |
| CO (1) | CO6270217A2 (enExample) |
| EC (1) | ECSP10010052A (enExample) |
| MA (1) | MA31706B1 (enExample) |
| MX (1) | MX2010003441A (enExample) |
| PE (1) | PE20090654A1 (enExample) |
| TN (1) | TN2010000135A1 (enExample) |
| TW (1) | TW200924737A (enExample) |
| WO (1) | WO2009045795A2 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2483718C2 (ru) * | 2007-09-28 | 2013-06-10 | Новартис Аг | Галеновые композиции алискирена |
| AR073651A1 (es) * | 2008-09-24 | 2010-11-24 | Novartis Ag | Formulaciones galenicas de compuestos organicos |
| KR20110129482A (ko) * | 2009-03-20 | 2011-12-01 | 노파르티스 아게 | 알리스키렌을 포함하는 제약 조성물 |
| CA2755487A1 (en) * | 2009-03-20 | 2010-09-23 | Novartis Ag | Galenical formulations of a fixed dose combination of valsartan and aliskiren |
| WO2011116115A1 (en) * | 2010-03-16 | 2011-09-22 | Novartis Ag | Aliskiren composition comprising a medium chain fatty acid, their process of manufacturing |
| TR201002256A1 (tr) * | 2010-03-24 | 2011-10-21 | Sanovel �La� Sanay� Ve T�Caret Anon�M ��Rket� | Stabil aliskiren formülasyonları |
| CN101926793B (zh) * | 2010-08-05 | 2012-08-15 | 成都自豪药业有限公司 | 一种含替米沙坦和阿利吉伦的联合用药物及其制备方法 |
| JP6267125B2 (ja) * | 2011-10-12 | 2018-01-24 | ダウ グローバル テクノロジーズ エルエルシー | 射出成型された剤形 |
| AU2012360935A1 (en) * | 2011-12-26 | 2014-07-17 | Novartis Ag | Tablets and dry-coated agents |
| CN103349652B (zh) * | 2013-05-11 | 2014-11-19 | 辽宁大学 | 含有四氢萘酰胺化合物或其可药用盐的高药物载荷片剂 |
| JP2023553010A (ja) | 2020-12-03 | 2023-12-20 | バテル・メモリアル・インスティテュート | 非ウイルス性送達のためのポリマーナノ粒子およびｄｎａナノ構造組成物ならびに方法 |
| WO2022216977A1 (en) | 2021-04-07 | 2022-10-13 | Batelle Memorial Institute | Rapid design, build, test, and learn technologies for identifying and using non-viral carriers |
| WO2025072751A1 (en) | 2023-09-29 | 2025-04-03 | Battelle Memorial Institute | Polymer nanoparticle compositions for in vivo expression of polypeptides |
| WO2025122954A1 (en) | 2023-12-08 | 2025-06-12 | Battelle Memorial Institute | Use of dna origami nanostructures for molecular information based data storage systems |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK469989D0 (da) * | 1989-09-22 | 1989-09-22 | Bukh Meditec | Farmaceutisk praeparat |
| GB9613470D0 (en) * | 1996-06-27 | 1996-08-28 | Ciba Geigy Ag | Small solid oral dosage form |
| US8168616B1 (en) * | 2000-11-17 | 2012-05-01 | Novartis Ag | Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension |
| US6669955B2 (en) * | 2001-08-28 | 2003-12-30 | Longwood Pharmaceutical Research, Inc. | Combination dosage form containing individual dosage units of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin |
| PE20110121A1 (es) * | 2004-03-17 | 2011-02-28 | Novartis Ag | Composiciones farmaceuticas de aliskiren |
| PL1799199T3 (pl) * | 2004-10-08 | 2012-09-28 | Novartis Ag | Zastosowanie inhibitorów reniny do zapobiegania lub leczenia dysfunkcji rozkurczowej albo rozkurczowej niewydolności serca |
| MY146830A (en) * | 2005-02-11 | 2012-09-28 | Novartis Ag | Combination of organic compounds |
| KR20080000624A (ko) * | 2005-04-27 | 2008-01-02 | 노파르티스 아게 | 아테롬성동맥경화증의 치료 방법 |
-
2008
- 2008-09-24 AR ARP080104137A patent/AR066168A1/es not_active Application Discontinuation
- 2008-09-24 TW TW097136690A patent/TW200924737A/zh unknown
- 2008-09-24 MX MX2010003441A patent/MX2010003441A/es not_active Application Discontinuation
- 2008-09-24 BR BRPI0817442-3A patent/BRPI0817442A2/pt not_active IP Right Cessation
- 2008-09-24 WO PCT/US2008/077416 patent/WO2009045795A2/en not_active Ceased
- 2008-09-24 JP JP2010527091A patent/JP2010540547A/ja not_active Withdrawn
- 2008-09-24 US US12/678,877 patent/US20100209480A1/en not_active Abandoned
- 2008-09-24 KR KR1020107006603A patent/KR20100063090A/ko not_active Withdrawn
- 2008-09-24 CA CA2698330A patent/CA2698330A1/en not_active Abandoned
- 2008-09-24 EP EP08835022A patent/EP2205233A2/en not_active Withdrawn
- 2008-09-24 CN CN200880108860A patent/CN101808631A/zh active Pending
- 2008-09-24 AU AU2008309058A patent/AU2008309058B2/en not_active Ceased
- 2008-09-24 PE PE2008001660A patent/PE20090654A1/es not_active Application Discontinuation
- 2008-09-24 CL CL2008002829A patent/CL2008002829A1/es unknown
-
2010
- 2010-03-17 MA MA32701A patent/MA31706B1/fr unknown
- 2010-03-26 TN TNP2010000135A patent/TN2010000135A1/fr unknown
- 2010-03-26 EC EC2010010052A patent/ECSP10010052A/es unknown
- 2010-04-19 CO CO10045487A patent/CO6270217A2/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| CO6270217A2 (es) | 2011-04-20 |
| AU2008309058B2 (en) | 2012-08-09 |
| EP2205233A2 (en) | 2010-07-14 |
| JP2010540547A (ja) | 2010-12-24 |
| TN2010000135A1 (en) | 2011-09-26 |
| CA2698330A1 (en) | 2009-04-09 |
| CN101808631A (zh) | 2010-08-18 |
| BRPI0817442A2 (pt) | 2015-06-16 |
| TW200924737A (en) | 2009-06-16 |
| KR20100063090A (ko) | 2010-06-10 |
| AR066168A1 (es) | 2009-07-29 |
| CL2008002829A1 (es) | 2009-06-26 |
| WO2009045795A3 (en) | 2009-07-16 |
| AU2008309058A1 (en) | 2009-04-09 |
| US20100209480A1 (en) | 2010-08-19 |
| ECSP10010052A (es) | 2010-04-30 |
| WO2009045795A2 (en) | 2009-04-09 |
| PE20090654A1 (es) | 2009-06-27 |
| MX2010003441A (es) | 2010-04-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA31706B1 (fr) | Formulations galéniques de composés organiques | |
| CY1126116T1 (el) | Φαρμακευτικες συνθεσεις αποτελουμενες απο νιλοτινιμπη | |
| CL2007003604A1 (es) | Composicion farmaceutica para administrar oral que comprende el compuesto 17-aminogeldanamicina amorfo; y su uso en el tratamiento del cancer. | |
| UA94942C2 (ru) | Фармацевтические композиции с ингибиторами dpp iv | |
| EA200900264A1 (ru) | Композиции флибансерина и способ их приготовления | |
| TW200833370A (en) | Pharmaceutical composition containing low substituted hydroxypropylcellulose | |
| NO20043367L (no) | Oralt farmasoytisk preparat | |
| HRP20120004T1 (en) | Dipeptidyl peptidase inhibitors for treating diabetes | |
| WO2010068810A3 (en) | Certain substituted amides, method of making, and method of use thereof | |
| BRPI0817275A2 (pt) | Combinação farmacêutica de alisquireno e valsartana | |
| CY1111470T1 (el) | Νεες φαρμακευτικες συνθεσεις που περιεχουν φλιβανσερινη πολυμορφη α | |
| MA35753B1 (fr) | Aryl-dihydropyridinones et pipéridinones en tant qu'inhibiteurs de mgat2 | |
| CL2008000750A1 (es) | Metodo para la administracion de una dosis semanal de 2-[6-(3-amino-piperidin-1-il)3-metil-2,4 dioxo-3,4 dihidro-2h-pirimidin-1-il metil]-4 fluoro-benzonitrilo; composicion farmaceutica de una forma de dosificacion individual de dicho compuesto; y su | |
| UA93709C2 (ru) | 12-имидазолил-1-додеканол и его применение b изготовлении фармацевтических композиций | |
| AR058085A1 (es) | Sal de dihidrogeno fosfato de un antagonista del receptor de prostaglandina d2. composiciones farmaceuticas. | |
| NO20074933L (no) | Farmasoytisk sammensetning som innbefatter et indolylmaleimidderivat | |
| NO20082047L (no) | Sakte frigivende sammensetning, fremgangsmate for fremstilling derav og anvendelse av samme | |
| WO2007131070A3 (en) | Compositions, dosage forms and methods of treating emesis | |
| UA97348C2 (en) | HETEROCYCLIC NF-kB INHIBITORS | |
| JO3239B1 (ar) | تركيبات جالينية من مركبات عضوية | |
| MXPA02010828A (es) | Composicion farmaceutica en capsulas que comprende un antiinflamatorio no esteroideo y un analgesico opiaceo para el manejo del dolor. | |
| CO5700723A2 (es) | Uso de un derivado de amina ciclica especifico o de sus sales farmaceuticamente aceptables para tratar y prevenir la insuficiencia cardiaca | |
| WO2007009691A3 (en) | Combination of substituted pyrazolines and anti -addictive agent | |
| ATE508737T1 (de) | Clopidogrel-hydrogensulfat von polymorph 1 form enthaltende pharmazeutische zusammensetzung | |
| NO20064783L (no) | Opplosningstabeletter med licarbazepin |